MX382970B - Molecula de unión al antígeno trifuncional - Google Patents

Molecula de unión al antígeno trifuncional

Info

Publication number
MX382970B
MX382970B MX2016013218A MX2016013218A MX382970B MX 382970 B MX382970 B MX 382970B MX 2016013218 A MX2016013218 A MX 2016013218A MX 2016013218 A MX2016013218 A MX 2016013218A MX 382970 B MX382970 B MX 382970B
Authority
MX
Mexico
Prior art keywords
antigen
binding molecule
antigenic epitope
binding
specificity against
Prior art date
Application number
MX2016013218A
Other languages
English (en)
Other versions
MX2016013218A (es
Inventor
Eugene Zhukovsky
Gall Fabrice Le
Kristina Ellwanger
Markus Eser
Melvyn Little
Michael Weichel
Thorsten Gantke
Uwe Reusch
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX382970(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of MX2016013218A publication Critical patent/MX2016013218A/es
Publication of MX382970B publication Critical patent/MX382970B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a una molécula de unión al antígeno triespecífica, en donde la molécula de unión al antígeno es al menos tetravalente y comprende un sitio de unión al antígeno que tiene especificidad contra un primer epítopo antigénico, un sitio de unión al antígeno que tiene especificidad contra un segundo epítopo antigénico y dos sitios de unión al antígeno que tienen especificidad contra un tercer epítopo antigénico y su uso como medicamento para terapia contra tumor.
MX2016013218A 2014-04-13 2015-04-12 Molecula de unión al antígeno trifuncional MX382970B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14164523.4A EP2930188A1 (en) 2014-04-13 2014-04-13 Trifunctional antigen-binding molecule
PCT/EP2015/057919 WO2015158636A1 (en) 2014-04-13 2015-04-12 Trifunctional antigen-binding molecule

Publications (2)

Publication Number Publication Date
MX2016013218A MX2016013218A (es) 2017-05-19
MX382970B true MX382970B (es) 2025-03-12

Family

ID=50478320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013218A MX382970B (es) 2014-04-13 2015-04-12 Molecula de unión al antígeno trifuncional

Country Status (13)

Country Link
US (2) US20170037128A1 (es)
EP (2) EP2930188A1 (es)
JP (1) JP6635940B2 (es)
KR (1) KR102392598B1 (es)
CN (1) CN106661108A (es)
AU (1) AU2015249006B2 (es)
BR (1) BR112016023362A2 (es)
CA (1) CA2945053A1 (es)
DK (1) DK3131928T4 (es)
MX (1) MX382970B (es)
RU (1) RU2753882C2 (es)
SI (1) SI3131928T2 (es)
WO (1) WO2015158636A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000525A1 (en) 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
KR20180012860A (ko) * 2015-06-15 2018-02-06 누맙 이노베이션 아게 이종 이량체 다중 특이적 항체 포맷
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
IL268554B2 (en) 2017-02-08 2025-03-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295C (en) 2017-02-20 2024-11-19 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20200325232A1 (en) * 2017-11-21 2020-10-15 Innate Pharma Multispecific antigen binding proteins
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
US12384847B2 (en) 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
US12215157B2 (en) 2018-02-20 2025-02-04 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
JP7288913B2 (ja) * 2018-03-14 2023-06-08 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019243453B2 (en) * 2018-03-27 2024-05-02 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
MA52777A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Agents de liaison psma et utilisations correspondantes
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53284A (fr) 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
JP2021534779A (ja) 2018-08-27 2021-12-16 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 抗体構築物がプレロードされた凍結保存ｎｋ細胞
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
EP4081554A1 (en) 2019-12-27 2022-11-02 Affimed GmbH Method for the production of bispecific fcyriii x cd30 antibody construct
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
TW202208428A (zh) 2020-05-06 2022-03-01 美商蜻蜓醫療公司 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CR20230229A (es) * 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
US11617767B2 (en) 2020-11-20 2023-04-04 Simcere Innovation, Inc. Armed dual CAR-T compositions and methods for cancer immunotherapy
PE20240761A1 (es) 2021-01-28 2024-04-17 Janssen Biotech Inc Proteinas de union a psma y usos de estas
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
EP0922111B1 (en) * 1996-07-23 2004-12-01 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE60124912T2 (de) * 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
IL162732A0 (en) * 2001-12-26 2005-11-20 Immunomedics Inc Methods of generating multispecific, multivalent agents from hv and vl domains
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
EP1976880B1 (en) * 2005-12-21 2016-07-06 Amgen Research (Munich) GmbH Pharmaceutical compositions with resistance to soluble cea
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
RU2570633C2 (ru) * 2009-05-27 2015-12-10 Ф.Хоффманн-Ля Рош Аг Три- или тетраспецифические антитела
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway

Also Published As

Publication number Publication date
AU2015249006B2 (en) 2020-10-29
AU2015249006A1 (en) 2016-10-20
DK3131928T3 (da) 2020-02-24
EP3131928B2 (en) 2023-04-05
RU2016138347A (ru) 2018-05-14
CN106661108A (zh) 2017-05-10
KR20160143739A (ko) 2016-12-14
WO2015158636A1 (en) 2015-10-22
SI3131928T2 (sl) 2023-05-31
MX2016013218A (es) 2017-05-19
KR102392598B1 (ko) 2022-04-29
RU2753882C2 (ru) 2021-08-24
CA2945053A1 (en) 2015-10-22
EP3131928B1 (en) 2019-11-20
US20170037128A1 (en) 2017-02-09
JP2017513476A (ja) 2017-06-01
WO2015158636A8 (en) 2016-11-17
DK3131928T4 (da) 2023-05-30
EP2930188A1 (en) 2015-10-14
BR112016023362A2 (pt) 2018-03-27
SI3131928T1 (sl) 2020-04-30
EP3131928A1 (en) 2017-02-22
RU2016138347A3 (es) 2018-12-04
US20220048994A1 (en) 2022-02-17
JP6635940B2 (ja) 2020-01-29

Similar Documents

Publication Publication Date Title
MX382970B (es) Molecula de unión al antígeno trifuncional
CY1123397T1 (el) Συνθεσεις που περιλαμβανουν συνδυασμο ιπιλιμουμαμπης και νιβολουμαμπης
CO2017001994A2 (es) Compuestos activos hacia bromodominios
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
MX2018014154A (es) Polinucleotidos moduladores.
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
MX2017014136A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
CL2015001772A1 (es) Composición farmacéutica para el tratamiento de dolor cabeza, y método de preparación de la misma.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201692554A1 (ru) Менингококковые вакцины
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
UY35747A (es) Derivados sustituidos de fenilalanina
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.